Lung Cancer Clinical Trials in Long Beach, CA

Lung Cancer Clinical Trials in Long Beach, CA

View the best 10 lung cancer medical studies in Long Beach, California. Access promising new therapies by applying to a Long Beach-based Lung Cancer clinical trial.

Trials in Long Beach, California

Here are the top 10 medical studies for lung cancer in Long Beach, California

Image of Massachusetts General Hospital in Boston, United States.

Lazertinib +2 More

Small Molecule Kinase Inhibitor

Recruiting2 awardsPhase 3
This trial is testing a new, easier to use formulation of amivantamab, which has the potential to reduce administration time and improve the patient and physician experience.
Image of Children's Hospital of Alabama in Birmingham, United States.

Thoracotomy +1 More

Procedure

Recruiting2 awardsPhase 3
This trial compares the effect of open thoracic surgery to thoracoscopic surgery in treating patients with osteosarcoma that has spread to the lung.
Image of Millennium Oncology Research Clinic ( Site 2801) in Hollywood, United States.

Pembrolizumab/Vibostolimab +4 More

Checkpoint Inhibitor

Recruiting2 awardsPhase 3
This trial tests a combination of two drugs, pembrolizumab and vibostolimab, along with standard chemotherapy and radiation in patients with advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can better control the disease and improve survival compared to another drug, durvalumab. These drugs help the immune system attack cancer cells more effectively.
Image of NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro in Jonesboro, United States.

Tepotinib

Kinase Inhibitor

Recruiting1 awardPhase 2
This trial tests a combination of drugs, tepotinib and ramucirumab, for treating patients with advanced non-small cell lung cancer that has spread or come back. Tepotin
Image of Sarcoma Oncology in Santa Monica, United States.

HBI-2438

Epigenetic Modulator

Recruiting1 awardPhase 1
This trial tests HBI-2438, an oral drug for patients with advanced solid tumors having the KRAS G12C mutation. The drug aims to stop cancer growth by blocking the faulty gene. Related drugs, Adagrasib and Sotorasib, have shown effectiveness in treating similar conditions.
Image of Virginia Cancer Specialists in Fairfax, United States.

Amivantamab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial tests a combination of two drugs, amivantamab and cetrelimab, in patients with a specific type of lung cancer. The treatment works by blocking cancer growth signals and helping the immune system fight the cancer. Amivantamab is a bispecific antibody that targets EGFR and MET, approved for treating non-small cell lung cancer with EGFR exon 20 insertion mutations.
Image of Research Site in Chandler, United States.

Ceralasertib +2 More

PARP Inhibitor

Recruiting3 awardsPhase 3
This trial tests a new combination of drugs (ceralasertib and durvalumab) against a standard treatment (docetaxel) in patients with advanced lung cancer who didn't respond to previous treatments. The new combination aims to weaken cancer cells and boost the immune system, while the standard treatment directly kills the cancer cells.
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Carotuximab +1 More

Monoclonal Antibodies

Recruiting2 awardsPhase 1
This trial is testing a combination of two drugs, osimertinib and carotuximab, to treat advanced EGFR-mutated non-small cell lung cancer. The goal is to find the maximum tolerated dose of the combination by measuring the number of dose-limiting toxicities. Secondary objectives include evaluating the rate of objective response, duration of response, progression-free survival, and disease control rate.
Image of University of California, Irvine in Orange, United States.

Amivantamab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial is testing a combination of two drugs to treat non-small cell lung cancer. The first part of the trial is to find the best dose of the combination, and the second part is to see how well the combination works.
Image of Desert Hematology Oncology Medical Group, Inc. in Rancho Mirage, United States.

Cemiplimab +4 More

Monoclonal Antibodies

Recruiting0 awardsPhase 2 & 3
This trial is testing a new drug called fianlimab with cemiplimab and chemotherapy in patients with advanced lung cancer. The goal is to see if this combination is more effective than current treatments. The new drugs help the immune system fight cancer, while chemotherapy attacks the cancer cells directly.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.